Filing Flows › Lineage Cell Therapeutics (LCTX) › Q2 2026
Lineage Cell Therapeutics (LCTX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Lineage Cell Therapeutics (LCTX) reported revenue of $1.1M for the second quarter 2026 (Q2 2026), -61% from a year earlier and -38% from the quarter before. Operating margin was -834.7%, net earnings $1.5M (144.4% of revenue).
Lineage Cell Therapeutics, Q2 2026: revenue $1.1M (-61% year over year), operating margin -834.7%, net earnings $1.5M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1M | -38% | -61% |
| Operating profit | −$8.9M | — | — |
| Net earnings | $1.5M | — | — |
| Operating cash flow | −$7.2M | — | — |
What changed
Revenue was $1.1M in Q2 2026, down 61% year over year and down 38% from the previous quarter. Upfront License Fees was the largest line at 56% of revenue. Upfront License Fees lost $1.9M year over year (down 76%), 114% of the total change.
Operating costs exceeded revenue by $8.9M, an operating margin of -834.7%. Total costs fell 56% while revenue fell 61%. The fastest-growing cost line was Research & development (+54%). Net earnings were $1.5M. The effective tax rate was 0.0%. Non-operating items added $10.5M, 678% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$7.2M. Non-cash charges added back $187K of depreciation and amortization and $1.6M of share-based compensation. Working capital and other items used $10.6M. Capital expenditures of $108K exceeded it, leaving free cash flow of −$7.4M.
Questions
What was Lineage Cell Therapeutics' revenue in the second quarter 2026?
Lineage Cell Therapeutics (LCTX) reported revenue of $1.1M for the second quarter 2026 (Q2 2026), -61% from a year earlier and -38% from the quarter before.
Was Lineage Cell Therapeutics profitable in the second quarter 2026?
Operating loss was $8.9M (-834.7% of revenue) and net earnings $1.5M.